In April 2009, the ICR revealed that damage to the BRAF gene could cause up to 70 per cent of melanoma skin cancers.
<p>In conjunction with the Royal Marsden, the ICR is currently testing a promising new prostate cancer drug called abiraterone, which it developed.
